Boston, MA, United States of America

Yixiang Zhang


 

Average Co-Inventor Count = 6.0

ph-index = 1


Location History:

  • Brighton, MA (US) (2014)
  • Boston, MA (US) (2015)

Company Filing History:


Years Active: 2014-2015

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Yixiang Zhang: Innovator in Cancer Treatment

Introduction

Yixiang Zhang is a prominent inventor based in Boston, MA (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of novel compounds. With a total of 3 patents, Zhang's work focuses on addressing hyperproliferative disorders, particularly cancer and its metastases.

Latest Patents

Zhang's latest patents include groundbreaking inventions such as quinoline derivatives as AXL kinase inhibitors. These novel compounds serve as inhibitors of receptor tyrosine kinases of the AXL receptor family, making them suitable for the treatment or prevention of disorders associated with hyperfunction of AXL family receptors. Additionally, he has developed quinolinyloxyphenylsulfonamides, which are useful for the prophylaxis, treatment, and after-treatment of hyperproliferative disorders, including cancer and tumors.

Career Highlights

Throughout his career, Yixiang Zhang has worked with esteemed organizations, including the Max Planck Society for the Advancement of Science. His research has led to significant advancements in the understanding and treatment of cancer, showcasing his dedication to improving patient outcomes.

Collaborations

Zhang has collaborated with notable scientists such as Axel Ullrich and László Örfi, further enhancing the impact of his research in the scientific community.

Conclusion

Yixiang Zhang's innovative work in developing compounds for cancer treatment highlights his commitment to advancing medical science. His contributions continue to pave the way for new therapeutic options in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…